A Feasibility Study of Internet Delivered Prolonged Exposure
1 other identifier
interventional
30
1 country
1
Brief Summary
The primary objective with this study is to investigate the feasibility and acceptability of ten weeks of internet delivered prolonged exposure delivered through a digital platform with therapist support. The secondary objective is to investigate preliminary effects of internet delivered prolonged exposure in terms of reducing symptoms of post-traumatic stress, depression and increase quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 23, 2022
CompletedFirst Posted
Study publicly available on registry
September 29, 2022
CompletedStudy Start
First participant enrolled
October 18, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 9, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 9, 2023
CompletedDecember 7, 2023
December 1, 2023
11 months
September 23, 2022
December 6, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (8)
Number of imaginal exposures made by the participant during the treatment period
Number of imaginal exposures made by the participant during the treatment
Through the treatment period, up to 10 weeks
Number of in vivo exposures made by the participant during the treatment period
Number of in vivo exposures made by the participant during the treatment period
Through the treatment period, up to 10 weeks
The proportion of participants that conducts the weekly measures and further assessment points
The proportion of participants that conducts the weekly measures and further assessment points
Through study completion up to the 6 months follow up]
The proportion of participants that go through the entire treatment period
The proportion of participants that go through the entire treatment period
Completion of the treatment period, ten weeks
Adverse events related to the treatment
Treatment acceptability
Through study completion, up to the 6 months follow up
Number of drop-outs from treatment
Treatment acceptability
Completion of the treatment period, up to 10 weeks
Participants experience/satisfaction with treatment and assessment procedures through qualitative interviews
Qualitative interviews
Completion of the treatment period up to the 6-month follow up
Participants satisfaction with treatment, assessed by The Client Satisfaction Questionnaire (CSQ-8).
The CSQ-8 yields a single score measuring a single dimension of overall satisfaction. An "overall score" is calculated by summing the score on each of the eight scale item. Scores range from 8 to 32, with higher values indicating higher satisfaction.
Completion of the treatment period, up to 10 weeks
Secondary Outcomes (5)
Change in PTSD symptoms as assessed by the Clinician Administered PTSD Scale (CAPS-5)
Baseline, 1 month and 6 months follow up
Change in PTSD symptoms as assessed by the PTSD Check List - DSM-5 (PCL-5)
Baseline, weekly through 10 weeks of treatment, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
Change in ICD-11 PTSD and complex PTSD symptoms as assessed by the International Trauma Questionnaire (ITQ).
Baseline, weekly through 10 weeks of treatment, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
Change in depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)
Baseline, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
Change in quality of life measured by Euroqol, EQ-5D
Baseline, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
Study Arms (1)
Internet delivered prolonged exposure
EXPERIMENTALInternet delivered prolonged exposure for ten weeks with therapist support.
Interventions
Internet delivered prolonged exposure for ten weeks with therapist support.
Eligibility Criteria
You may qualify if:
- Currently primary diagnosis PTSD according to DSM-5 diagnostic criteria for PTSD
- ≥ 18 years
- Fluent in Swedish
- Signed informed consent
You may not qualify if:
- PTSD is not the primary concern
- Initiation or adjustment of any psychotropic medication within the last 4 weeks prior to commencement of treatment
- Ongoing substance dependence
- Current suicide risk meriting crisis intervention
- Psychotic disorder
- Ongoing trauma-focused psychological treatment
- Ongoing trauma-related threat (e.g. living with a violent spouse)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Karolinska Institutetlead
- Region Stockholmcollaborator
Study Sites (1)
Traumaprogrammet, Psykiatri Sydväst
Stockholm, Sweden
Related Publications (1)
Bragesjo M, Ivanov VZ, Andersson E, Ruck C. Exploring the feasibility and acceptance of huddinge online prolonged exposure therapy (HOPE) for severe and complex PTSD. Eur J Psychotraumatol. 2024;15(1):2320607. doi: 10.1080/20008066.2024.2320607. Epub 2024 Mar 4.
PMID: 38436944DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Maria Bragesjö, PhD
Karolinska Institutet
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
September 23, 2022
First Posted
September 29, 2022
Study Start
October 18, 2022
Primary Completion
September 9, 2023
Study Completion
September 9, 2023
Last Updated
December 7, 2023
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will not share